Vantrexa · NSCLC · United States · Thoracic medical oncologist · captured by James Whitfield on 02 Jun 2026 · reviewed by Dr. Priya Raman on 04 Jun 2026
Verbatim as captured; never edited
At ASCO, several KOLs commented that the competitor TIGIT programme's negative Phase III readout has increased scepticism about the class, and asked how the vantrelimab mechanism differs.
Human-approved by Dr. Priya Raman on 04 Jun 2026
Competitor TIGIT failure raising class scepticism; KOLs request clear mechanistic differentiation. Recommend scientific platform update and reactive slide.
No AI assistance
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 2 | 20% | 8.0 |
| Strategic alignment | 5 | 20% | 20.0 |
| Scientific importance | 4 | 15% | 12.0 |
| Urgency | 4 | 15% | 12.0 |
| Novelty | 3 | 10% | 6.0 |
| Actionability | 5 | 10% | 10.0 |
| Confidence | 5 | 5% | 5.0 |
| Breadth of occurrence | 5 | 5% | 5.0 |
| Total | Critical 78 | ||
| Time | Action | User | Field | Change | Reason | Source |
|---|---|---|---|---|---|---|
| 11 Sept 2026, 14:21 UTC | Close | JWJames Whitfield | topics | In progress → In progress | — | API |
| 20 Jul 2026, 10:05 UTC | Close | PRDr. Priya Raman | status | Outcome recorded → Closed | Mechanistic module approved in platform v3.2 | UI |
| 04 Jun 2026, 09:15 UTC | Route | PRDr. Priya Raman | routedTo | — → Medical Communications | Competitor class scepticism requires platform update | UI |
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
Insight
Reviewed 04 Jun 2026 by Dr. Priya Raman
Medical Communications · David Chen · due 31 Jul 2026 · Completed
Launch-readiness workstream · David Chen · In progress
Decision
Outcome
Content update · INI-0105
Closure
Mechanistic differentiation module added to core scientific platform v3.2 (approved 2026-07-18). Reactive standard response SR-VTX-019 approved.
16 Jan 2026 · IT · MSL interaction